Last reviewed · How we verify
NCT07504445
Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors
EARLY_PHASE1 trial testing CAR-DC treatment in Advanced Solid Tumors in 10 participants. Currently enrolling.
3 April 2028
Quick facts
| Lead sponsor | Peking University Shenzhen Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 3 April 2026 |
| Primary completion | 3 April 2028 |
| Estimated completion | 3 April 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- CAR-DC treatment
Conditions studied
- Advanced Solid Tumors — all drugs for Advanced Solid Tumors →
Sponsor
Peking University Shenzhen Hospital
Who can join
Adults 18 to 70, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, open label, single arm clinical trial to evaluate the safety and the preliminary efficacy of chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of advanced solid tumors positive for one of the following antigens: ephrin type-A receptor 2 (EphA2), claudin-18 isoform 2 (CLDN18.2) , trophoblast cell surface antigen 2 (Trop2), human epidermal growth factor receptor 2 (HER2), guanylyl cyclase-C (GCC), glypican-3 (GPC3) and carcinoembryonic antigen (CEA).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07504445
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Tumors
Currently open trials in the same condition.
- NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
- NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07349160 — Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Sol · EARLY_PHASE1 · recruiting
Other Peking University Shenzhen Hospital trials
Trials by the same sponsor.
- NCT07374614 — Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib · recruiting
- NCT07089173 — The Effect-site Concentration of Remifentanil Blunting Endotracheal Intubation Responses During Anesthesia Induction Wit · NA · recruiting
- NCT07135336 — Incidence of Postoperative Cognitive Decline in Patients With Preexisting Cognitive Impairment · recruiting
- NCT07110428 — Supraglottic Jet Oxygenation Ventilation During Hysteroscopic Surgery · NA · enrolling by invitation
- NCT07294989 — The Effective Blood Concentration of Ciprofol · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07504445 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Shenzhen Hospital
- Last refreshed: 31 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07504445.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing